NGLFINE2,701.00

NGL Fine-Chem Limited

· Pharma & Health
₹ CrorePeersSYNCOMFJAGSNPHARMHESTERBIOAMRUTANJANWINDLASINDOCOSAIPARENTMcap ₹1,669 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt32.473.2108.4108.4
Net Debt-21.512.966.466.4
Total Debt/Equity0.120.260.330.33
Net Debt/Equity-0.080.050.200.20
Total Debt/EBITDA0.612.161.491.49
Net Debt/EBITDA-0.400.380.910.79
Interest Coverage (EBIT/Interest)31.119.1811.8911.89
Total Debt/Total Capital %10.9920.5724.7724.77
As Filed — company-reported covenants
Debt/Equity (as filed)0.37
Debt Service Coverage (as filed)0.03
Interest Service Coverage (as filed)13.41
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.